This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Semaglutide, the popular drug sold by Novo Nordisk as ...
Pfizer has a lofty goal for the CDK4 inhibitor atirmociclib, the New York pharma’s answer to Ibrance’s loss of patent ...
On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...
The drug, which one analyst described as a “critical” part of Pfizer’s oncology strategy, represents a possible improvement ...
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...
The second round of Medicare negotiations are here, with the Centers for Medicare and Medicaid (CMS) unveiling the new maximum fair prices for the 15 drugs Tuesday. The list of drugs includes obesity ...
Highly coveted weight-loss related diabetes drugs produced by Danish drugmaker Novo Nordisk are among the medications that will be subject to price controls by Medicare. On Friday, the Centers for ...
The moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew ...
Rachel Cohrs Zhang reported on the intersection of health policy and business in Washington. She covered Capitol Hill, lobbying, and federal agencies. Her primary areas of focus were the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results